Detalhe da pesquisa
1.
A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma.
Br J Cancer
; 129(5): 811-818, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37488446
2.
Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort study.
Pigment Cell Melanoma Res
; 36(5): 388-398, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37243929
3.
Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL).
Melanoma Res
; 32(5): 343-352, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35762583
4.
BRAF V600E mutational load as a prognosis biomarker in malignant melanoma.
PLoS One
; 15(3): e0230136, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32168325
5.
Serum markers improve current prediction of metastasis development in early-stage melanoma patients: a machine learning-based study.
Mol Oncol
; 14(8): 1705-1718, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32485045
6.
Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review.
Melanoma Manag
; 6(4): MMT33, 2019 Oct 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31871622
7.
The Circulating Transcriptome as a Source of Biomarkers for Melanoma.
Cancers (Basel)
; 11(1)2019 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30634628
8.
Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study.
Medicine (Baltimore)
; 96(52): e9523, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29384960
9.
A study on MSH2 and MLH1 mutations in hereditary nonpolyposis colorectal cancer families from the Basque Country, describing four new germline mutations.
Fam Cancer
; 8(4): 533-9, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19760518